Multidisciplinary Management of Metastatic Sarcoma

Surgical Clinics of North America

Volumn 88, Issue 3, 2008, Pages 661-672

  Thornton, Katherine ^a   Pesce, Catherine E ^b   Choti, Michael A ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; MITOMYCIN;

ADENOCARCINOMA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; HUMAN; LEIOMYOSARCOMA; LIMB TUMOR; LIVER METASTASIS; LUNG METASTASIS; LUNG RESECTION; MONOTHERAPY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SOFT TISSUE SARCOMA; TUMOR LOCALIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MESNA; SARCOMA; TREATMENT OUTCOME;

EID: 44349178585     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.04.002     Document Type: Review

References (66)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics 2002. CA Cancer J Clin 52 (2002) 23-47
2. Coindre J.M., Terrier P., Bui N.B., et al. Prognostic factors in adult patient with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14 3 (1996) 869-877
3. Gadd M.A., Casper E.S., Woodruff J.M., et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg 218 6 (1993) 705-712
4. Coindre J.M., Terrier P., Guillou L., et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer 91 10 (2001) 1914-1926
5. Pisters P.W., Leung D.H., Woodruff J., et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14 5 (1996) 1679-1689
6. Stojadinovic A., Leung D.H., Hoos A., et al. Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas. Ann Surg 235 3 (2002) 424-434
7. Lewis J.J., and Brennan M.F. Soft tissue sarcomas. Curr Probl Surg 33 10 (1996) 817-872
8. Billingsley K., Burt M., Jara E., et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of disease and postmetastasis survival. Ann Surg 229 5 (1999) 602-612
9. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350 9092 (1997) 1647-1654
10. Komdeur R., Hoekstra H., van den Berg E., et al. Metastasis in soft tissue saracomas: prognostic criteria and treatment perspectives. Cancer Metastasis Rev 21 (2002) 167-183
11. Trovik C., Bauer H., Alvegar T., et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 36 6 (2000) 710-716
12. McKee M., Liu D., Brooks J., et al. The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol 85 2 (2004) 68-76
13. Rosenberg S., Tepper J., Glatstein E., et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196 3 (1982) 305-315
14. Olieman A., Pras E., van Ginkel R., et al. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 40 4 (1998) 807-814
15. Casson A., Putnam J., Natarajan G., et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer 69 3 (1992) 662-668
16. Verazin G., Warneke J., Driscoll D., et al. Resection of lung metastases from soft-tissue sarcomas: a multivariate analysis. Arch Surg 127 12 (1992) 1407-1411
17. van Geel A., van Coevorden F., Blankensteijn J., et al. Surgical treatment of pulmonary metastases from soft tissue sarcomas: a retrospective study in The Netherlands. J Surg Oncol 56 3 (1994) 172-177
18. Putnam Jr. J., Roth J., Wesley M., et al. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 87 2 (1984) 260-268
19. Jablons D., Steinberg S., Roth J., et al. Metastasectomy for soft tissue sarcoma: further evidence for efficacy and prognostic indicators. J Thorac Cardiovasc Surg 97 5 (1989) 695-705
20. Weiser M., Downey R., Leung D., et al. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 191 3 (2000) 184-190
21. van Geel A., Pastorino U., Jauch K., et al. Surgical treatment of lung metastases: the European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 77 (1996) 675-682
22. Temple L., and Brennan M. The role of pulmonary metastasectomy in soft tissue sarcoma. Semin Thorac Cardiovasc Surg 114 (2002) 35-44
23. Laganè D., Carrafiello G., Mangini M., et al. Radiofrequency ablation of primary and metastatic lung tumors: preliminary experience with a single center device. Surg Endosc 20 (2006) 1262-1267
24. Gillams A.R., Lees W.R., Mangini M., et al. Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol 18 (2008) 672-677
25. Espat N.J., Bilsky M., Lewis J.J., et al. Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients. Cancer 94 (2002) 2706-2711
26. Pingpank Jr. J.F., Hoffman J.P., Sigurdson E.R., et al. Pancreatic resection for locally advanced primary and metastatic nonpancreatic neoplasms. Am Surg 94 (2002) 337-340 [discussion 340-1]
27. Chen H., Pruitt A., Nicol T., et al. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 2 2 (1998) 151-155
28. Harrison L., Brennan M., and Newman E. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 121 6 (1997) 625-632
29. Adam R., Chiche L., and Aloia T. Association Française de Chirurgie, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244 (2006) 524-535
30. Mentzer S., Antman K., Attinger C., et al. Selected benefits of thoracotomy and chemotherapy for sarcoma metastatic to the lung. J Surg Oncol 53 (1993) 54-59
31. Pastorino U. Metastasectomy for soft tissue sarcomas. In: Verweij J., Pinedo H., and Suit H. (Eds). Soft tissue sarcomas: present achievement and future prospects (1997), Kluwer Academic Publishers, Boston 65-75
32. Baxter G., Alvegard T., and Monge O. VIG chemotherapy in advanced soft tissue sarcoma-results of the Scandinavian Sarcoma Group SSG-X trial. Acta Orthop Scand Suppl 265 (1995) 93-94
33. Porter G., Cantor S., Walsh G., et al. Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M.D. Anderson and Memorial Sloan-Kettering Cancer Centers. J Thorac Cardiovasc Surg 127 (2004) 1366-1372
34. Chao C., and Goldberg M. Surgical treatment of metastatic pulmonary soft-tissue sarcoma. Oncology (Williston Park) 14 6 (2000) 835-841 [discussion: 842-4, 847]
35. D'Adamo D.R., Anderson S.E., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23 28 (2005) 7135-7142
36. O'Bryan R.M., Luce J.K., Talley R.W., et al. Phase II evaluation of adriamycin in human neoplasia. Cancer 32 1 (1973) 1-8
37. O'Bryan R.M., Baker L.H., Gottlieb J.E., et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 39 5 (1977) 1940-1948
38. Gottlieb J.A., Benjamin R.S., Baker L.H., et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60 2 (1976) 199-203
39. Gottlieb J.A., Baker L.H., Quagliana J.M., et al. Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 30 6 (1972) 1632-1638
40. Pinedo H.M., and Kenis Y. Chemotherapy of advanced soft-tissue sarcomas in adults. Cancer Treat Rev 4 2 (1977) 67-86
41. Gottlieb J.A. Proceedings: combination chemotherapy for metastatic sarcoma. Cancer Chemother Rep 58 2 (1974) 265-270
42. Borden E.C., Amato D.A., Rosenbaum C., et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5 6 (1987) 840-850
43. Benjamin R.S. Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma?. J Clin Oncol 5 6 (1987) 833-835
44. Bramwell V.H., Mouridsen H.T., Santoro A., et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 31 Suppl 2 (1993) S180-S184
45. Scheef W., Klein H.O., Brock N., et al. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 63 3 (1979) 501-505
46. Stuart-Harris R.C., Harper P.G., Parsons C.A., et al. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11 2 (1983) 69-72
47. Bramwell V.H., Mouridsen H.T., Santoro A., et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23 3 (1987) 311-321
48. Elias A., Ryan L., Sulkes A., et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7 9 (1989) 1208-1216
49. Legha S.S., Benjamin R.S., Mackay B., et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96 2 (1982) 133-139
50. Von Burton G., Rankin C., Zalupski M.M., et al. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol 29 1 (2006) 59-61
51. Antman K., Crowley J., Balcerzak S.P., et al. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11 7 (1993) 1276-1285
52. Edmonson J.H., Ryan L.M., Blum R.H., et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11 7 (1993) 1269-1275
53. Edmonson J.H., Long H.J., Richardson R.L., et al. Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. Cancer Chemother Pharmacol 15 2 (1985) 181-182
54. Steward W.P., Verweij J., Somers R., et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11 1 (1993) 15-21
55. Steward W.P., Verweij J., Somers R., et al. The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 31 Suppl 2 (1993) S241-S244
56. Hensley M.L., Maki R., Venkatraman E., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20 12 (2002) 2824-2831
57. Patel S.R., Gandhi V., Jenkins J., et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19 15 (2001) 3483-3489
58. Maki R.G., Wathen J.K., Patel S.R., et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25 19 (2007) 2755-2763
59. Bay J.O., Ray-Coquard I., Fayette J., et al., Groupe Sarcome Français. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 119 3 (2006) 706-711
60. Gabizon A.A., Barenholz Y., and Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10 5 (1993) 703-708
61. Gabizon A., Catane R., Uziely B., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54 4 (1994) 987-992
62. Northfelt D.W., Martin F.J., Working P., et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36 1 (1996) 55-63
63. Skubitz K.M. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 21 2 (2003) 167-176
64. Judson I., Radford J.A., Harris M., et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37 7 (2001) 870-877
65. Nielsen O.S., Reichardt P., Christensen T.B., et al. Phase I European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer 42 14 (2006) 2303-2309
66. Talbot S.M., Keohan M.L., Hesdorffer M., et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 98 9 (2003) 1942-1946